This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
- Veteran global finance leader adds institutional investment, capital markets and strategic transaction expertise to NetraMark
Sign In or Create an Account
or View more offersArticle content
TORONTO, Sept. 08, 2026 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Kevin Felix as Strategic Advisor, strengthening the senior strategic and institutional experience surrounding the Company as NetraMark advances its commercialization strategy.
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
Mr. Felix brings more than 25 years of senior leadership experience across capital markets, asset management, corporate strategy and securities law. Most recently, Mr. Felix served as President of the Investment Office of Global Atlantic Financial Group, responsible for all business management and operational matters related to the firm’s $175 billion investment portfolio. Prior thereto, his senior positions at Scotiabank included President and CEO of Scotia Capital (USA) Inc. and Global Head of Fixed Income, Currencies, and Commodities, a diverse multi-billion dollar business throughout North and South America, Europe and Asia. Mr. Felix also brings extensive corporate governance experience, having served as independent director for several firms.
Article contentArticle content
“Kevin has operated at a high level within the global financial markets,” said George Achilleos, CEO of NetraMark. “As we advance commercialization and broaden the Company’s relationships across the pharmaceutical and investment communities we are continuing to strengthen the level of experience around the organization. Kevin is an exceptional addition.”
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
“NetraMark has developed a highly differentiated approach to applying artificial intelligence to one of the pharmaceutical industry’s most significant challenges: understanding patient heterogeneity within clinical trials,” said Kevin Felix, Strategic Advisor to NetraMark. “I am excited to work with George and the NetraMark team as they continue building the Company, developing important industry relationships and evaluating the strategic and capital markets opportunities that may accompany its growth.”
Article content
Supporting NetraMark’s Next Stage of Growth
Article content
As Strategic Advisor, Mr. Felix will advise NetraMark on various matters including Canadian and U.S. institutional investor and investment banking relationships, strategic transactions, corporate development and longer-term capital markets strategy.
Article content
Mr. Felix holds a Masters of Law in Securities Regulation from Georgetown University Law Center, a Juris Doctor, cum laude, from New York Law School, and a Bachelor of Arts from Bucknell University.
Article content
For more information on NetraMark and NetraAI, visit www.netramark.com.